Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.

Abstract

A phase II study using vindesine (3 mg/m2 by slow intravenous push at seven to 14 day intervals) was carried out in 42 patients with metastatic melanoma. There was one complete remission (2.5%) of greater than 12 months duration; seven partial remissions (17.5%) of two, three, three, four, five, six and eight months duration; 11 with no change (27.5%) of one to 10 months duration; and 21 (52.5%) patients with increasing disease. Toxicity included neutropenia, neurotoxicity, phlebitis and cellulitis at the site of injection, alopecia, fever and chills, myalgias, and gastrointestinal toxicity. It was concluded that vindesine does have activity in some patients with metastatic malignant melanoma. Further studies in previously untreated patients are warranted.

• Authors: J M Quagliana, R L Stephens, L H Baker, J J Costanzi
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 2 Issue 4 Pg. 316-9 (Apr 1984) ISSN: 0732-183X [Print] United States
• PMID: 6707719 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Vinblastine
• Vindesine

Topics

• Adult
• Aged
• Drug Evaluation
• Female
• Gastrointestinal Diseases (chemically induced)
• Humans
• Leukopenia (chemically induced)
• Lung Neoplasms (drug therapy, secondary)
• Lymphatic Metastasis
• Male
• Melanoma (drug therapy, secondary)
• Middle Aged
• Nervous System Diseases (chemically induced)
• Skin Neoplasms (drug therapy, secondary)
• Thrombocytopenia (chemically induced)
• Vinblastine (adverse effects, analogs & derivatives, therapeutic use)
• Vindesine